Evaluation of HS-20137 in Chinese Patients with Moderate-to-Severe Psoriasis: Results from a Phase 2, Randomized, Double-Blind Trial - Summary - MDSpire

Evaluation of HS-20137 in Chinese Patients with Moderate-to-Severe Psoriasis: Results from a Phase 2, Randomized, Double-Blind Trial

  • By

  • Lin Cai

  • Xiaohua Wang

  • Litao Zhang

  • Guoqiang Zhang

  • Liming Wu

  • Baoqi Yang

  • Zudong Meng

  • Jihai Shi

  • Guangming Han

  • Aihua Wei

  • Shanshan Li

  • Yi Zhao

  • Juan Su

  • Nianjin Wei

  • Siying Liu

  • Ran Liu

  • Wei Liu

  • Min Fang

  • Xiaoqing Zhang

  • Jianzhong Zhang

  • March 22, 2026

  • 0 min

Share

Objective:

To evaluate the safety and efficacy of HS-20137, a monoclonal antibody targeting IL-23, over 52 weeks in Chinese patients with moderate-to-severe psoriasis.

Key Findings:
  • HS-20137 significantly improved psoriatic lesions and quality of life, with statistical significance.
  • The treatment demonstrated an excellent long-term therapeutic effect and safety profile, comparable to existing IL-23 therapies.
  • Findings support further development of HS-20137 as a competitive treatment option for psoriasis.
Interpretation:

HS-20137 shows promise as an effective treatment for moderate-to-severe psoriasis, with potential advantages over existing IL-23 therapies in terms of dosing frequency and safety.

Limitations:
  • The study did not perform a sample size estimation, which may affect the power of the results.
  • Results are based on a specific population (Chinese patients), which may limit generalizability to other populations.
  • Potential biases in participant selection and reporting may affect the findings.
Conclusion:

HS-20137 is a promising candidate for the treatment of moderate-to-severe psoriasis, warranting further investigation.

Original Source(s)

Evaluation of HS-20137 in Chinese Patients with Moderate-to-Severe Psoriasis: Results from a Phase 2, Randomized, Double-Blind Trial

  • by Lin Cai, Xiaohua Wang, Litao Zhang, Guoqiang Zhang, Liming Wu, Baoqi Yang, Zudong Meng, Jihai Shi, Guangming Han, Aihua Wei, Shanshan Li, Yi Zhao, Juan Su, Nianjin Wei, Siying Liu, Ran Liu, Wei Liu, Min Fang, Xiaoqing Zhang, Jianzhong Zhang

  • March 22, 2026

Related Content

Cupping vs UVB: Comparable Psoriasis Outcomes?

Randomized study found no statistically significant differences in disease improvement between treatments over 8 weeks.

Evaluation of the Safety and Efficacy of Scheduled Temporary Withdrawal Versus Ongoing Maintenance of Interleukin Inhibitors in Psoriasis Patients: A Systematic Review and Network Meta-Analysis

Development and Validation of the Visual Medical Scale to Evaluate Nail Psoriasis Severity (ViSENPsO®)